161.53
-2.28 (-1.39%)
| Previous Close | 163.81 |
| Volume | 806,466 |
| Price / Earnings (Forward) | 1.67 |
| Price / Sales | 15.49 |
| Price / Book | 14.16 |
| 52 Weeks Range |
| Profit Margin | -30.57% |
| Operating Margin (TTM) | -19.39% |
| Diluted EPS (TTM) | -2.27 |
| Quarterly Revenue Growth (YOY) | 24.60% |
| Total Debt/Equity (MRQ) | 14.09% |
| Current Ratio (MRQ) | 6.49 |
| Operating Cash Flow (TTM) | -45.97 M |
| Levered Free Cash Flow (TTM) | -17.66 M |
| Return on Assets (TTM) | -6.68% |
| Return on Equity (TTM) | -20.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Glaukos Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -1.25 |
|
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.33% |
| % Held by Institutions | 101.71% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| NAVRATIL TOMAS | - | 163.47 | -1,457 | -238,176 |
| Aggregate Net Quantity | -1,457 | |||
| Aggregate Net Value ($) | -238,176 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 163.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NAVRATIL TOMAS | Officer | 16 Sep 2026 | Automatic sell (-) | 1,457 | 163.47 | 238,176 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |